Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 9/20 | 0.58 |
| ▸ | MAOA | P21397 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GUSB | P08236 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099199 | 1.00 | MAPT (1.00) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL4094409 | 0.84 | MEN1 (0.73) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL4094410 | 0.84 | MEN1 (0.73) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL4090447 | 0.81 | GAA (0.70) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL4090450 | 0.81 | GAA (0.70) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL4090442 | 0.81 | GAA (0.70) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL12643697 | 0.77 | MAPT (1.00) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL30294200 | 0.74 | MAPT (0.74) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL4098410 | 0.74 | MEN1 (0.68) | MAPTLMNAMEN1KMT2AGAA | |
| SCHEMBL4098407 | 0.74 | MEN1 (0.68) | MAPTLMNAMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS PARC SCIENTIFIQUE LUMINY (FR) | 2009-08-13 | — | — | US | claimed |
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS PARC SCIENTIFIQUE LUMINY (FR) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | NLN, NQO1, APP | MAPT 31/4885LMNA 2447/4885MEN1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.